高级检索
当前位置: 首页 > 详情页

Clinicopathological characteristics and prognosis of metaplastic breast cancer versus triple-negative invasive ductal carcinoma: a retrospective analysis

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Hebei Medical University, Shijiazhuang, China [2]Department of Breast Cancer Center, The Fourth Hospital of Hebei Medical University, No. 12, Jian‑Kang Road, Shijiazhuang 050011, China
出处:
ISSN:

关键词: Metaplastic breast cancer Triple-negative invasive ductal carcinoma Clinicopathological characteristics Prognosis

摘要:
Metaplastic breast cancer(MBC) is a specific pathological type of invasive breast cancer. There are few studies related to MBC due to its rarity. This study aimed to analyse the differences in clinicopathological characteristics and prognosis between Metaplastic breast cancer and triple-negative invasive ductal carcinoma (TN-IDC).We retrospectively compared the clinicopathological characteristics of patients diagnosed with MBC and TN-IDC at the Fourth Hospital of Hebei Medical University between 2011 and 2020 in a 1:2 ratio. The log-rank test was used to compare the two groups' disease-free survival (DFS) and overall survival (OS). For MBCs, we performed univariate and multivariate analyses using the Cox proportional hazards model to determine the characteristics that impacted OS and DFS.A total of 81 patients with MBC and 162 patients with TN-IDC were included in this study. At initial diagnosis, MBC patients had larger tumour diameters(P = 0.03) and fewer positive lymph nodes (P = 0.04). Patients with MBC were more likely to have organ metastases after surgery (P = 0.03). Despite receiving the same treatment, MBC patients had worse DFS (HR = 1.66, 95%CI 0.90-3.08, P = 0.11) and OS (HR = 1.98, 95% CI 1.03-3.81, P = 0.04), and OS was statistically significant. Positive lymph nodes at initial diagnosis were associated with worse DFS (HR = 3.98, 95%CI 1.05-15.12, P = 0.04) and OS (HR = 3.70, 95%CI 1.03-13.34, P = 0.04) for patients with MBC. The efficacy of platinum-based agents is insensitive for MBC patients receiving chemotherapy. In addition, patients treated with preoperative chemotherapy had worse DFS compared to patients treated with postoperative chemotherapy (HR = 3.51, 95%CI 1.05-11.75, P = 0.04).The clinicopathological characteristics and prognosis of MBC and TN-IDC differ in many ways. Further studies are required to determine suitable treatment guidelines for patients with MBC.© 2023. The Author(s).

语种:
WOS:
PubmedID:
中科院分区:
出版当年[2023]版:
大类 | 3 区 医学
小类 | 3 区 肿瘤学 3 区 外科
最新[2025]版:
大类 | 3 区 医学
小类 | 3 区 肿瘤学 3 区 外科
JCR分区:
出版当年[2023]版:
Q1 SURGERY Q3 ONCOLOGY
最新[2024]版:
Q1 SURGERY Q3 ONCOLOGY

影响因子: 最新[2024版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版] 出版后一年[2024版]

第一作者:
第一作者机构: [1]Hebei Medical University, Shijiazhuang, China [2]Department of Breast Cancer Center, The Fourth Hospital of Hebei Medical University, No. 12, Jian‑Kang Road, Shijiazhuang 050011, China
通讯作者:
通讯机构: [2]Department of Breast Cancer Center, The Fourth Hospital of Hebei Medical University, No. 12, Jian‑Kang Road, Shijiazhuang 050011, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:42329 今日访问量:0 总访问量:1365 更新日期:2025-08-01 建议使用谷歌、火狐浏览器 常见问题

技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号